We have given our Drug Tariff Monitor an overhaul, redesigned to operate under the same layout as our therapeutic reports and incorporating more data and we would appreciate any feedback you may have. A draft version of the new report based on November 2018 prices is now available on our website for download (after logging in select ‘Cost Impact and Savings’ and ‘Drug Tariff Monitor’). To provide any feedback, queries or comments about the content of the new report, please do not hesitate to contact us at firstname.lastname@example.org
Published: Thu, 13 Dec 2018 13:06:17 +0000
We have re-produced a report updated for the NHS England consultation on 'items which should not be routinely prescribed in primary care' with prescribing data up to September 2018. This is now available via the RDTC website (Click here to access the website). After logging in, the report can be accessed via the ‘Cost Impact and Savings - Cost Impact Estimates Reports’ headings. If you have any queries or comments about the content of this report, please do not hesitate to contact us at email@example.com
Published: Fri, 07 Dec 2018 14:08:29 +0000
Our new reports 'Top 50 Expenditure' (comprising top 50 BNF drugs and top 50 BNF sections) for the period April 2018 to September 2018 are now online. These documents are available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Reports menu, click on the Top 50 Expenditure link).
Published: Thu, 06 Dec 2018 13:03:35 +0000
Our new report 'Potential Generic Savings' for the period July 2018 to September 2018 is now online. This document is available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Prescribing Analysis Reports menu, click on the Cost Impact and Savings menu item and then on Potential Generic Savings).
Published: Thu, 06 Dec 2018 12:50:06 +0000
The latest Prescribing Support Update Newsletter is now online. Topics covered include cannabis-based products for medicinal use, topiramate and contraception and pregabalin and gabapentin to be reclassified as class c controlled substances.
Please see our Update Newsletter page.
Published: Thu, 29 Nov 2018 10:26:51 +0000
The New Drug Evaluation for Cariprazine for the treatment of schizophrenia in adults is now online. This publication provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this new product.
Visit our New Drug Evaluations page.
Published: Tue, 27 Nov 2018 10:13:25 +0000
September 2018 reports are now online. These documents are available to our stakeholders only (username and password required). Access is via the 'Financial Headlines' link in the Prescribing Analysis Reports section of this site.
Published: Fri, 23 Nov 2018 10:41:09 +0000
Our November 2018 Monthly Horizon Scanning Report is now available. Please see our Monthly Horizon Scanning Reports page.
Published: Thu, 15 Nov 2018 14:50:19 +0000
We have given our Drug Tariff Monitor an overhaul, redesigned to operate under the same layout as our therapeutic reports and incorporating more data and we would appreciate any feedback you may have. The draft version of the new report based on October 2018 prices is now available on our website for download (after logging in select ‘Cost Impact and Savings’ and ‘Drug Tariff Monitor’). To provide any feedback, queries or comments about the content of the new report, please do not hesitate to contact us at firstname.lastname@example.org
Published: Mon, 12 Nov 2018 16:36:09 +0000
Our Cost Comparison Charts and Switch Saving Calculators have been updated for November 2018 following the amendment to Category M reimbursement prices on 1st November 2018. The latest Excel, Word and PDF versions of the Cost Comparison Charts are available to our stakeholders only (user and password required). The charts are located here.
The Switch Saving Calculators are also available to stakeholders only. Access is via the Prescribing Analysis Reports menu, under the Cost Impact and Savings submenu item.
Published: Mon, 12 Nov 2018 16:28:41 +0000
Bayer have announced plans to permanently discontinue nifedipine immediate-release 5mg & 10mg capsules (Adalat) in 2019. There are no other nifedipine immediate-release products licensed in the UK. The NHS Specialist Pharmacy Service have published an updated memo with advice on alternatives to immediate-release nifepidine, as well as information about the temporary supply issues with several Bayer modified-release nifedipine products (Adalat Continue Reading »Memos and Alerts News Prescribing Newsletter
Published: Tue, 04 Dec 2018 17:28:34 +0000
Bricanyl Turbohaler is the ONLY terbutaline inhaler marketed in the UK. Astra Zeneca UK Ltd have notified the Department of Health and Social Care of a temporary shortage and interruption to supplies. Some stock may be available during December 2018, but the shortage is unlikely to be fully resolved until the end of January 2019. The NHS Specialist Continue Reading »Memos and Alerts News Prescribing Newsletter Respiratory
Published: Mon, 03 Dec 2018 17:59:59 +0000
NICE have published the results of a consultation on proposals to update the Key Therapeutic Topics collection of resources in 2019 – with a final list of the topics to be included.
The post NICE Key Therapeutic Topics 2019 – Consultation Result appeared first on NECS Medicines Optimisation.Memos and Alerts News Prescribing Newsletter
Published: Mon, 03 Dec 2018 17:31:11 +0000
NICE have published the latest addition to the growing suite of resources on antibiotic prescribing for common infections: a guide to treating catheter-associated urinary tract infections (CAUTIs). The guideline includes recommendations on: treatment advice when an antibiotic prescription is given reassessment referral and seeking specialist advice self-care choice of antibiotic prevention Like other NICE Antibiotic Use Guidelines, the CAUTI Continue Reading »
The post Catheter-Associated UTIs – new NICE Antibiotic Use Guideline appeared first on NECS Medicines Optimisation.Antibiotics Memos and Alerts News Prescribing Newsletter
Published: Mon, 03 Dec 2018 17:21:32 +0000
Regulations governing prescription of gluten-free foods in England changed on 1st December 2018. Community pharmacies can now only supply specified bread products and bread/flour mixes (see list here). ALL other gluten-free foods have been added to Part XVIIIA of the Drug Tariff – the ‘Blacklist’. NHS England have published guidance for CCGs with linked FAQs that may help Continue Reading »Memos and Alerts News Prescribing Newsletter gluten-free
Published: Mon, 03 Dec 2018 14:33:53 +0000
Oral lidocaine-containing products for infant teething are only to be available under the supervision of a pharmacist so that parents and caregivers can receive guidance about managing infant teething symptoms.
Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need to regularly check for (and report) any suspicious skin lesions or moles.
In patients at risk for aortic aneurysm and dissection, fluoroquinolones should only be used after careful assessment of the benefits and risks and after consideration of other therapeutic options.
Sildenafil is not authorised for use in pregnancy for the treatment of intrauterine growth restriction.
Reporting suspected adverse drug reactions to the Yellow Card Scheme helps to support the safe use of medicines in babies, children, and pregnant and breastfeeding women.
Letters were sent to healthcare professionals about Jext adrenaline autoinjectors, rivaroxaban, Ozurdex 700 micrograms intravitreal implant, sildenafil, hydrochlorothiazide, and Epilim Chronosphere (sodium valproate).
An alert was recently issued by MHRA about CoaguChek Test Strips for Point of Care and Home Use due to a risk of false high results.
Rivaroxaban treatment in patients who undergo transcatheter aortic valve replacement (TAVR) should be stopped and switched to standard of care.
Monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month after starting and ending ritonavir treatment.
Interrupt treatment if posterior reversible encephalopathy syndrome (PRES) is confirmed and resume treatment only once the event is resolved and the benefit of continued treatment outweighs the risk of PRES.
Northern Treatment Advisory Group: http://ntag.nhs.uk/html/latest_news.html